Substance + claimed effects

Added sugars are caloric sweeteners introduced into foods and drinks during processing or preparation: sucrose (table sugar), high-fructose corn syrup (HFCS), glucose syrup, dextrose, agave nectar, honey added to a product, fruit-juice concentrates, and dozens of trade names that resolve to the same monosaccharide load (cane crystals, evaporated cane juice, brown rice syrup, etc.). The WHO's overlapping free sugars definition also pulls in honey, syrups, and the sugars in fruit juice WHO 2015. The functional unit, biologically, is the disaccharide sucrose (50% glucose, 50% fructose) or the close-cousin HFCS-55 (55% fructose, 45% glucose) — the two dominant industrial sweeteners; both deliver a near-equimolar dose of glucose and fructose to the portal circulation, and their downstream metabolic effects are indistinguishable in controlled feeding.

Claimed and evidenced consequences, scoped to this entry: (i) acute and chronic glycemic burden and (via beverage form) type-2-diabetes incidence; (ii) weight gain via liquid-calorie under-compensation; (iii) elevated fasting and postprandial triglycerides; (iv) dose-dependent dental caries; (v) liver fat accumulation (hepatic de novo lipogenesis driven specifically by the fructose moiety); (vi) skin glycation contributing to long-term collagen damage and acne-correlated insulin/IGF-1 signalling; (vii) cardiovascular and all-cause mortality at the upper end of intake; (viii) modest blood-pressure elevation and (less well-established) mood/depression risk via SSB intake. Energy, focus, and sleep are touched indirectly through the blood-glucose rollercoaster and metabolic-syndrome chain rather than as primary effects — the article holds them as second-order, scored conservatively.

Evidence by addressing question

mechanism

Glucose vs fructose are metabolically distinct. Glucose is taken up by every tissue under insulin control; about 20% reaches the liver on first pass. Fructose, by contrast, is absorbed via GLUT5 and routed almost entirely through the portal vein to the liver — the only organ with appreciable ketohexokinase (KHK) activity. KHK phosphorylates fructose to fructose-1-phosphate without the rate-limiting feedback that controls glucose flux through phosphofructokinase, so a fructose load bypasses the liver's normal carbohydrate brake and floods the substrate pool for de novo lipogenesis (DNL) Stanhope et al., JCI 2009.

De novo lipogenesis is the central link. In Stanhope et al.'s 10-week feeding trial, overweight/obese adults consuming fructose-sweetened beverages at 25% of energy gained the same weight as a glucose-sweetened group but specifically grew visceral fat, became insulin-resistant, raised 23-hour postprandial triglyceride AUC, and elevated DNL — none of which occurred in the glucose arm Stanhope et al., JCI 2009. Schwarz et al. then isolated the effect from energy balance: in a 9-day isocaloric trial, swapping starch for sugar (fructose cut from ~12% to ~4% of calories) in obese children dropped fasting DNL area-under-curve from 68% to 26% and reduced liver fat irrespective of weight change Schwarz et al., Gastroenterology 2017. The Lustig group's parallel Obesity trial in the same population showed isocaloric sugar restriction normalised triglycerides (−33 mg/dL), LDL-C (−10 mg/dL), fasting insulin (−53%), and blood pressure (−5 mmHg DBP) inside nine days Lustig et al., Obesity 2016. Together these establish that added-sugar harm is not just a calorie story; the fructose moiety has its own pathway.

Caries is a local-substrate mechanism. Streptococcus mutans and other plaque organisms metabolise sucrose, glucose, and fructose to organic acids (lactic, acetic) that drop plaque pH below the demineralisation threshold (~5.5) for enamel hydroxyapatite. The damage is dose- and frequency-dependent: sticky sugars and continuous sipping prolong the acid attack; fluoride raises the demineralisation threshold but does not eliminate it Moynihan & Kelly, J Dent Res 2014.

Glycation is the chronic-collagen mechanism. Glucose and fructose react non-enzymatically with amine groups on long-lived proteins (collagen, elastin) to form Schiff bases that mature into advanced glycation end products (AGEs). AGE-modified collagen is cross-linked, brittle, and resistant to enzymatic turnover; in skin, this contributes to loss of elasticity and the characteristic "sugar sag" phenotype, accelerated by UV exposure. Fructose glycates ~7–10× faster than glucose Danby, Clin Dermatol 2010.

Liquid sugar under-compensates. Calories delivered as drinks do not register on subsequent appetite the way solid-food calories do — the receptors that signal satiety key on volume, viscosity, and chewing, all minimal in a soda. The net result is additional caloric intake on top of the day's solid food, repeatedly replicated in feeding trials Malik et al., AJCN 2013.

evidence

Body weight. Te Morenga et al.'s 2013 BMJ meta-analysis of 30 RCTs and 38 cohort studies found that isocaloric exchange of sugars for other carbohydrates had no effect on weight, but ad libitum addition or subtraction of sugars produced a 0.8 kg weight gain or 0.8 kg weight loss respectively over the trial period Te Morenga et al., BMJ 2013. The signal is dose-dependent and reverses on removal. Malik et al.'s 32-study meta-analysis pinned the SSB-specific contribution: one extra daily serving was associated with 0.22 kg/year of weight gain in adults and a 0.06-unit BMI rise in children Malik et al., AJCN 2013.

Type-2 diabetes. Imamura et al.'s 2015 BMJ meta-analysis pooled 17 prospective cohorts and found one daily SSB serving was associated with a 13% higher T2D incidence after adjustment for adiposity, suggesting an adiposity-independent pathway (consistent with the DNL/visceral-fat mechanism above); the population-attributable fraction over 10 years was estimated at ~1.8 million US cases and ~80,000 UK cases Imamura et al., BMJ 2015.

Cardiovascular mortality. Yang et al.'s 2014 JAMA Internal Medicine analysis of NHANES III mortality linkage found a dose-response association: adults consuming 10–24.9% of energy from added sugars had 30% higher CVD-mortality hazard than those below 10%; those at ≥25% had 2.75-fold higher hazard. The relationship held after adjustment for total energy, BMI, and lifestyle covariates Yang et al., JAMA Intern Med 2014.

Lipids and blood pressure. Te Morenga et al.'s 2014 RCT meta-analysis: higher vs lower sugar intake raised triglycerides by 0.11 mmol/L (~10 mg/dL), total cholesterol by 0.16 mmol/L, and LDL-C by 0.12 mmol/L; in trials ≥8 weeks, systolic and diastolic BP rose by 6.9 and 5.6 mmHg respectively at the high-vs-low contrast Te Morenga et al., AJCN 2014.

Caries. Moynihan & Kelly's WHO-commissioned systematic review of 55 studies found a consistent positive dose-response between sugars intake and caries across the lifespan, with caries rates lower when intake was below 10% of energy and lower still when below 5% — the basis for the WHO conditional 5% recommendation Moynihan & Kelly, J Dent Res 2014.

Liver fat. Beyond Schwarz 2017 and Lustig 2016 (above), Stanhope 2009 demonstrated specific DNL induction by fructose in adults at 25%-of-energy doses; the mechanism is settled and the dose-response is replicated across cohorts and feeding trials. NAFLD prevalence tracks SSB intake at a population scale.

protocol

Three converging consensus thresholds: the WHO strong recommendation is <10% of energy from free sugars, with a conditional further reduction to <5% — about 25 g/day on a 2,000-kcal diet WHO 2015. The 2020–2025 US Dietary Guidelines for Americans set <10% of energy from added sugars — about 50 g (12 tsp) on a 2,000-kcal diet DGA 2020–2025. The American Heart Association 2009 scientific statement is tighter: ≤100 kcal/day (~25 g, 6 tsp) for women and ≤150 kcal/day (~36 g, 9 tsp) for men Johnson et al., Circulation 2009. The AHA's 2017 pediatric statement caps children 2–18 at ≤25 g/day and recommends no added sugar below age 2 Vos et al., Circulation 2017.

Operational protocol that does most of the work without counting grams: cut sugar-sweetened beverages to zero or near-zero. SSBs (soda, energy drinks, sweetened iced tea, sweetened coffee, sports drinks, fruit-juice "cocktails") are the leading category in the US food supply, accounting for ~24% of all added-sugar intake; the next category is desserts and sweet snacks CDC 2024. Read labels for the line "Added Sugars" mandated on the US Nutrition Facts panel since 2020. A single 12-oz can of regular soda contains ~39 g — already over the AHA women's daily cap.

contraindications

This is a reduction intervention; there is no medical contraindication to lowering added sugar. Two flag-cases for the article: (i) people on insulin or sulfonylureas for diabetes who suddenly cut sugar without dose adjustment can hypoglycaem — adjust pharmacology with a clinician; (ii) history of eating disorders — rigid food rules can recur restrictive patterns; the harm-reduction framing (cut SSBs, eat whole-food sweets you enjoy) is the safer prescription.

misconceptions

"Natural sugar is fine, added sugar is bad." The molecule is identical — the body cannot tell honey-fructose from corn-syrup-fructose. What differs is delivery: whole fruit packages sugar with fiber, water, and chew, slowing absorption and reducing satiety failure; the same sugar in juice or syrup is metabolically equivalent to added sugar and is in fact classified as free sugar by the WHO WHO 2015.

"Fruit juice is healthy." Fruit juice raises T2D risk on the same trajectory as SSBs in Imamura et al., once adjustment is made — a 100% orange juice glass is sugar-water with vitamins Imamura et al., BMJ 2015.

"It's just calories." Stanhope 2009 and Schwarz 2017 are the two studies that refute this most cleanly: at matched calories, fructose builds visceral fat and liver fat that glucose does not, and isocaloric sugar restriction normalises metabolic parameters in nine days. The "a calorie is a calorie" frame survives in the obesity literature for total energy, but added sugar carries metabolic costs that aren't captured in the calorie balance Stanhope et al., JCI 2009 Schwarz et al., Gastroenterology 2017.

"Sugar is addictive like cocaine." Overstated. Animal models show binge-eating patterns and dopaminergic adaptation in nucleus accumbens with intermittent sucrose access; the human evidence for clinical addiction (tolerance, withdrawal, loss of control as defined by DSM substance-use criteria) is much weaker. The honest framing is that highly palatable food drives habit and overconsumption, with reward-system involvement, not formal substance dependence.

"HFCS is uniquely bad; cane sugar is fine." The fructose:glucose ratios are similar (HFCS-55: 55:45; sucrose: 50:50), and controlled comparisons find equivalent metabolic effects. The HFCS-specific scare is a marketing artifact; the indictment is on added sugar generally.

audience

Children. The AHA recommends no added sugar before age 2 and ≤25 g/day for children 2–18 Vos et al., Circulation 2017. Pediatric NAFLD prevalence has tracked the rise in SSB intake; the Schwarz and Lustig trials were specifically in obese children with metabolic syndrome and demonstrated rapid reversal on sugar restriction Schwarz et al., Gastroenterology 2017 Lustig et al., Obesity 2016.

People with NAFLD, metabolic syndrome, T2D, or hypertriglyceridemia. Sugar restriction is one of the most impactful single dietary changes — see the rapid LFT improvements in the children's trials; the same mechanism applies to adults.

Pregnancy. Maternal high-SSB intake is associated with higher offspring obesity risk via gestational weight and offspring metabolic programming; not enough RCT data to score quantitatively but the direction is settled.

alternatives

Non-nutritive sweeteners (aspartame, sucralose, stevia, monk fruit) deliver sweet taste without the glucose/fructose load. WHO's 2023 non-sugar-sweetener guideline issued a conditional recommendation against their use for weight control on the basis of long-term observational data; the trade-off is contested. For weight loss, cluster RCTs do show better outcomes substituting NNS-sweetened beverages for SSBs, but the population effect is small. The honest framing: NNS are a less-harmful drop-in replacement, not a positive health choice; the ideal substitute is water, sparkling water, unsweetened tea/coffee, or whole fruit.

Whole fruit. Whole-fruit intake is inversely associated with T2D in the same cohorts where juice and SSBs are positively associated — the fiber/structure of the cellular matrix slows fructose absorption and triggers satiety. Use it as the sweet-craving replacement.

failure-modes

The hidden-sugar shock. Most reduction failures come from not realising where added sugar lives. Bread, pasta sauce, yogurt (especially "fruit on the bottom"), salad dressing, ketchup, granola, breakfast cereal, and almost every processed sauce carries added sugar. A "healthy" smoothie can deliver 50+ g.

The replacement-with-juice failure. Quitting soda for orange juice swaps one form of free sugar for another at near-equivalent metabolic cost Imamura et al., BMJ 2015.

The fat-free trap. Fat-free reformulated products (yogurt, salad dressing, baked goods) typically substitute sugar for fat to maintain palatability; calorie content barely drops and added-sugar load rises.

Compensation by other carbs. Replacing sugar with refined starch (white bread, white rice, processed snacks) loses the fructose-specific harm but does not restore satiety or metabolic health. The whole-food-fiber complex matters.

practicalities

Label literacy. The FDA's mandatory "Added Sugars" line on the Nutrition Facts panel (since 2020 for large manufacturers, 2021 for small) makes hidden sugars visible — the single most actionable practical change. The number to know: 4 g of sugar = 1 teaspoon.

The drinks-first heuristic. Cutting sweetened beverages alone moves a typical US adult from ~17 tsp/day (~68 g) below the DGA cap CDC 2024. It is the single highest-leverage move.

Policy context. Sugar taxes work at the population level: Mexico's 1-peso/L SSB excise drove a 5.5% decline in taxed-beverage purchases in year 1 and 9.7% in year 2, with the largest reductions in the lowest-income tertile (–14.3% by year 2) Colchero et al., Health Aff 2017. The UK Soft Drinks Industry Levy (2018) drove industry-side reformulation that removed 8 g sugar/household/week and was associated with an 8% relative reduction in obesity in Year-6 girls. These results inform individual behaviour: the policy lever exists because the substance does meaningful population harm.

history

Per-capita sugar availability in the US rose from ~4 lb/year in 1700 to ~150 lb/year by 1980, then plateaued at ~100 lb/year as HFCS substituted for sucrose in beverages. The current decline since the early 2000s is real but added-sugar intake remains roughly double the AHA recommendation CDC 2024. The historical thread matters because the human metabolic system evolved on intermittent honey-and-fruit; sustained high fructose loads at industrial scale are an evolutionary novelty.

stakes

The felt experience of sustained added-sugar intake unfolds across timescales: days — postprandial glucose excursions and reactive hypoglycemia (the 3pm crash); weeks — visceral fat accumulation, fasting triglyceride creep, acne flares in susceptible individuals; months — fatty liver development (often silent), early insulin resistance, cavities; years — T2D, hypertension, dyslipidemia, accelerated skin glycation; decade — cardiovascular mortality risk scaled to intake (Yang's 2.75x at ≥25%-of-energy intake) Yang et al., JAMA Intern Med 2014. The skeptic version of stakes: most of these endpoints are also driven by total energy excess, sedentary behaviour, and refined carbohydrate generally — added sugar is one mechanism among several. The honest read is that added sugar is a privileged lever because (a) the fructose-DNL pathway is uniquely harmful at matched calories and (b) it is concentrated in beverages that bypass satiety regulation.

payoff

The intervention is unusually fast-acting on metabolic markers. Within nine days of isocaloric sugar restriction, obese children with metabolic syndrome saw triglycerides drop 33 mg/dL, fasting insulin halve, DBP fall 5 mmHg, and liver fat measurably decline Lustig et al., Obesity 2016 Schwarz et al., Gastroenterology 2017. Adults see analogous if smaller changes on weeks-scale: weight loss when SSBs are eliminated ad libitum (–0.8 kg in Te Morenga 2013 trials), triglyceride normalisation, energy stability across the afternoon. Years-scale: lower T2D and CVD trajectories per the cohort data above. Cosmetic: caries arrest, slowed glycation-driven skin damage.

out-of-scope

Adjacent entries this one points toward: sugar-sweetened beverages (own entry candidate), non-nutritive sweeteners (own entry candidate), NAFLD (own entry), low-carb / ketogenic diets (own entry), insulin resistance, dental hygiene, alcohol (which has a structurally similar fructose-DNL pathway).

The credibility range

The optimist case for sugar restriction

The strongest pro-restriction case: added sugar is a uniquely privileged lever because (i) the fructose-DNL pathway has been shown to drive visceral fat, liver fat, dyslipidemia, and insulin resistance at matched calories (Stanhope 2009, Schwarz 2017, Lustig 2016 — three controlled trials, two of them isocaloric); (ii) the dose-response on CVD mortality (Yang 2014) and T2D (Imamura 2015) is consistent and adjustment-resistant; (iii) the mechanism is biologically coherent; (iv) population-scale natural experiments (Mexico, UK SDIL) demonstrate that reducing the substance reduces measurable disease markers. The intervention is cheap, fast-acting on metabolic markers (nine days), and the upper bound of plausible benefit is large (the CVD-mortality HR at ≥25%-of-energy intake is 2.75).

The skeptic case

The strongest counter: most population-level evidence is observational and confounded by overall dietary quality, energy excess, and lifestyle co-variates (the high-sugar consumer also eats more ultra-processed food, exercises less, smokes more). At isocaloric exchange with starch, sugar's effect on body weight is null (Te Morenga 2013) — most of the obesity story is calories, not sugar specifically. The fructose-uniqueness narrative leans heavily on a small number of feeding trials with supra-physiologic 25%-of-energy doses; at typical intake levels, the marginal harm over starch is modest. Sievenpiper and the "sugar realist" group have published meta-analyses showing minimal isocaloric harm at recommended intakes. The animal-model addiction literature does not extrapolate to clinical addiction. The hard cardiometabolic endpoints (CVD events, T2D incidence) lack large-scale RCTs of sugar restriction — what we have are surrogate-marker trials and cohorts.

The author's call

Land mostly on the optimist side, hedged: the fructose-DNL mechanism is real and replicable, the dose-response on CVD mortality is large enough to overwhelm reasonable confounding bands, and the felt-experience and metabolic-marker payoffs are fast and concrete. The skeptic's correction is taken seriously on one point: isocaloric substitution of sugar with refined starch buys less than restriction-from-ultra-processed-foods-altogether, so the practical intervention is reducing SSBs and ultra-processed sweets — not chasing a perfect macronutrient mix. Evidence quality: 4/5 (strong cohort + mechanistic + small RCT support; lacking a definitive hard-endpoint RCT, which will likely never be ethical to run). Controversy: 2/5 — the field broadly agrees added sugar is over-consumed and reduction is beneficial; disagreements are about magnitude, mechanism specificity, and whether sugar is uniquely worse than refined starch.

Stakeholder + incentive map

• Beverage and processed-food industries — direct commercial incentive to maintain consumption; fund research on alternative explanations (physical inactivity, total calories), oppose sugar taxes and front-of-pack warning labels. Coca-Cola's funding of the Global Energy Balance Network is the canonical case study.
• Sugar growers and HFCS producers — commodity-protection lobbying.
• Public-health bodies (WHO, AHA, USDA, NICE, AAP) — institutional alignment on reduction; the WHO 2015 guideline was actively opposed by industry-funded counter-evidence.
• Dental profession — settled consensus that sugar restriction is a primary caries prevention.
• Endocrinology / hepatology — increasing alignment on sugar as a NAFLD driver, partially through fructose-DNL evidence.
• Low-carb / keto community — pro-restriction, sometimes overstating the case to "all carbs are sugar."
• Mainstream nutrition academia — splits between sugar-uniqueness camp (Lustig, Stanhope, Hu) and energy-balance generalists (Sievenpiper, Khan); the calorie skeptic position survives in a minority of high-quality groups.

Population variability

• Baseline metabolic state. The Schwarz/Lustig trials showed dramatic improvement in already metabolically-unwell children; lean metabolically-healthy adults consuming moderate sugar (≤10% energy) likely see far smaller marginal effects.
• Genetic variation in fructose handling. KHK polymorphisms and rare disorders of fructose metabolism (hereditary fructose intolerance) produce extreme phenotypes; common variants produce modest differences in DNL response.
• Children vs adults. Children appear to show faster and larger metabolic responses to both sugar loading and restriction.
• Sex. The AHA recommendation is sex-stratified (25 g female / 36 g male) on the basis of total energy needs, not differential physiology Johnson et al., Circulation 2009.
• Acne susceptibility. Insulin and IGF-1 elevation from high-glycemic-load eating is the proposed pathway; adolescents and those with acne-prone skin show the clearest response to glycemic restriction Smith et al., AJCN 2007.
• Pregnant women and infants. Special caps; see audience.

Knowledge gaps

• No large-scale RCT of added-sugar restriction with hard cardiovascular endpoints — likely never feasible. The CVD-mortality evidence will remain epidemiological.
• Mechanism-specific dose-response at typical intake levels (5–15% of energy) is under-studied; almost all feeding trials use 25%-of-energy doses for effect-size visibility.
• Long-term safety and cardiometabolic effects of non-nutritive sweeteners are still being characterised; the WHO 2023 NSS guideline reflects uncertainty more than settled harm.
• Whether isocaloric substitution of sugar with refined starch (most likely real-world swap) buys meaningful metabolic improvement is contested — Te Morenga 2014's effect sizes suggest yes for lipids, but the absolute magnitude is small.
• The acne-glycation skin literature is dominated by mechanistic and small-trial evidence; large-scale RCTs of sugar restriction for skin outcomes do not exist.
• Sugar-addiction-as-clinical-syndrome remains unresolved; the human evidence does not yet support a DSM-criteria addiction diagnosis even where the behavioural pattern resembles one.

The brief named eight consequences (blood glucose, weight, triglycerides, dental caries, liver fat, skin, metabolic risk, and the sweetened-beverages/snack/condiment delivery surface). All eight are covered in the article body, with weight and triglycerides folded into the broader cardiometabolic case rather than getting their own headings — the dose-response evidence and the felt-experience cascade unite them. No part of the brief was silently dropped.

The article's analytic spine is the fructose-vs-glucose distinction (Stanhope 2009 → Schwarz 2017 → Lustig 2016 isocaloric chain). Without that spine, the entry collapses into a "watch your calories, kids" piece that doesn't earn the dose-response numbers. The dossier carries the mechanism in more detail than the article projects; the article uses one science callout and three references where the dossier uses six.

Rating calls worth flagging:

• Evidence at 4, not 5. The cohort + meta-analytic + small-RCT base is strong, but a definitive hard-endpoint RCT of added-sugar restriction would never be ethical, so the literature will not get to a Cochrane-grade 5. Capped honestly.
• Longevity at 4, not 5. Yang 2014's 2.75x CVD-mortality HR at the top intake band is dramatic, but it's observational. A 5 would require population-scale mortality bending, which a single dietary lever rarely achieves alone — sugar restriction is one of the bigger ones, but not the singular one (the score is shared with sleep, exercise, smoking-cessation, etc.).
• Effort burden at 3. Conservative average. For a once-a-week soda drinker, this is closer to 1; for a four-Coke-a-day reader, closer to 4. The article handles this by leading with the drinks-first heuristic, which makes the actual effort distribution roughly bimodal.
• Mood at 2. The SSB-depression meta-analyses are observational and modest in effect size; the mechanism (HPA-axis activation, post-prandial dysregulation) is plausible but not nailed. Held to 2 rather than 3 on that hedge.
• Beauty_direct at 2. Driven almost entirely by Smith 2007 acne RCT. The score would be higher in acne-prone populations and lower in those who don't get acne; 2 is the population-average call.
• Cost burden at 0. Reduction saves money on average; could arguably be negative if the schema allowed it.

Future-entry candidates (flagged for backlog, would each cross-link from this entry once they exist):

• Sugar-sweetened beverages — the highest-leverage subcategory; deserves its own deeper read on dose, formulation, and the SSB-specific epidemiology.
• Non-nutritive sweeteners — the 2023 WHO guideline and the unresolved literature on aspartame/sucralose/stevia warrant a dedicated entry rather than the one-paragraph treatment here.
• Non-alcoholic fatty liver disease — the silent endpoint several sections in this entry point at. Should be its own entry once the diagnostic protocol (FibroScan, FIB-4, ALT trends) can be unpacked properly.
• Glycemic load and acne — the Smith 2007 thread could anchor a focused entry on diet and skin.
• Sugar taxes (policy) — Mexico/UK natural experiments are referenced here as evidence of population-scale effect; a policy-side entry would cover the implementation literature.

Hard choices during the write:

• Considered combining stakes/payoff into one passage; kept them separate because the dose-response in Yang 2014 and the nine-day reversal in Lustig 2016 are both strong enough to earn their own felt-experience treatments at opposite poles of the article.
• Considered a separate audience block for children given the AHA 2017 pediatric statement and pediatric NAFLD epidemiology, but the article's audience is adult and the pediatric thread is folded into evidence/mechanism. A separate children-and-sugar entry could be the right home if the topic warrants it.
• The "sugar is addictive like cocaine" misconception is handled by debunking rather than endorsing; the human evidence does not support the strong claim. A reviewer who reads the recent neuroimaging literature might push back; the dossier flags this in the credibility range.
• Did not link out to the FDA Added Sugars label specification — house style is no outbound links; the reader has the panel in front of them at the supermarket.